Skip to content
10-Q

Quarterly Report

ATOSSA THERAPEUTICS, INC. ATOS

0001193125-26-213423

← back to feed
Filed
May 8, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 1, 2026 8.61M sh
Shares Diluted Q1 2026 · Mar 31, 2026 8.62M sh
Shares Diluted restated Q1 2026 · Mar 31, 2025 8.62M sh
Capex Q1 2026 · Mar 31, 2026 $0
Capex Q1 2026 · Mar 31, 2025 $9K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$9.58M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$5.96M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $31.72M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $41.3M
Cash And Equivalents Q1 2026 · Mar 31, 2025 $65.12M
Stockholders Equity Q1 2026 · Mar 31, 2026 $30.49M
Stockholders Equity Q1 2026 · Dec 31, 2025 $39.35M
Stockholders Equity Q1 2026 · Mar 31, 2025 $65.32M
Stockholders Equity Q1 2026 · Dec 31, 2024 $71.48M
Current Liabilities Q1 2026 · Mar 31, 2026 $7.46M
Current Liabilities Q1 2026 · Dec 31, 2025 $8.26M
Total Liabilities Q1 2026 · Mar 31, 2026 $7.46M
Total Liabilities Q1 2026 · Dec 31, 2025 $8.26M
Current Assets Q1 2026 · Mar 31, 2026 $36.67M
Current Assets Q1 2026 · Dec 31, 2025 $45.62M
Total Assets Q1 2026 · Mar 31, 2026 $37.94M
Total Assets Q1 2026 · Dec 31, 2025 $47.61M
Eps Diluted Q1 2026 · Mar 31, 2026 −$1.11
Eps Diluted restated Q1 2026 · Mar 31, 2025 −$0.78
Eps Basic Q1 2026 · Mar 31, 2026 −$1.11
Eps Basic restated Q1 2026 · Mar 31, 2025 −$0.78
Sga Expense Q1 2026 · Mar 31, 2026 $5.09M
Sga Expense Q1 2026 · Mar 31, 2025 $3.26M
Rd Expense Q1 2026 · Mar 31, 2026 $4.78M
Rd Expense Q1 2026 · Mar 31, 2025 $4.16M
Net Income Q1 2026 · Mar 31, 2026 −$9.59M
Net Income Q1 2026 · Mar 31, 2025 −$6.72M
Operating Income Q1 2026 · Mar 31, 2026 −$9.87M
Operating Income Q1 2026 · Mar 31, 2025 −$7.41M